1. Home
  2. CNM vs PRAX Comparison

CNM vs PRAX Comparison

Compare CNM & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Core & Main Inc.

CNM

Core & Main Inc.

HOLD

Current Price

$46.85

Market Cap

9.1B

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$296.64

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNM
PRAX
Founded
1996
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Durable Goods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1B
9.6B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
CNM
PRAX
Price
$46.85
$296.64
Analyst Decision
Buy
Strong Buy
Analyst Count
11
15
Target Price
$61.91
$572.13
AVG Volume (30 Days)
2.1M
313.3K
Earning Date
03-24-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.94
N/A
Revenue
$7,441,000,000.00
N/A
Revenue This Year
$4.21
N/A
Revenue Next Year
$4.50
$6,395.88
P/E Ratio
$24.41
N/A
Revenue Growth
11.03
N/A
52 Week Low
$43.18
$26.70
52 Week High
$67.18
$354.87

Technical Indicators

Market Signals
Indicator
CNM
PRAX
Relative Strength Index (RSI) 28.53 43.55
Support Level $43.96 $290.36
Resistance Level $54.95 $322.32
Average True Range (ATR) 1.57 16.54
MACD -0.32 -2.93
Stochastic Oscillator 10.61 28.46

Price Performance

Historical Comparison
CNM
PRAX

About CNM Core & Main Inc.

Core & Main is a leading specialty distributor with a focus on water, wastewater, storm drainage, and fire protection products. The company provides solutions to municipalities, private water companies, and professional contractors across municipal, nonresidential, and residential end markets. The company's specialty products and services are used in the maintenance, repair, replacement, and construction of water and fire protection infrastructure.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: